FDA Releases New Policy

FDA Commissioner, Scott Gottlieb, M.D. released a statement back in August 2017 saying, “One of the most promising new fields of science and medicine is the area of cell therapies and their use in regenerative medicine.” Dr. Gottlieb went on to say that the FDA needs to take steps to ensure patients are not deceived by deceptive producers and the responsible product developers have a comprehensive policy framework to follow. The FDA released the new policy on the oversight of stem cell therapies and regenerative medicine in November 2017. You can read the FDA’s full policy framework by clicking below.
FDA Policy Framework